Seroatlas · Human Serome Atlas

BTLA

B- and T-lymphocyte attenuator

Also known as: BTLA_HUMAN, BTLA1, CD272

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q7Z6A9
Gene: BTLA
Ensembl: ENSG00000186265
Chromosome: 3
Canonical length: 289 aa
Protein class: CD markers, Predicted membrane proteins, Predicted secreted proteins
Secretome location: Secreted to blood

OverviewNCBI Gene

This gene encodes a member of the immunoglobulin superfamily. The encoded protein contains a single immunoglobulin (Ig) domain and is a receptor that relays inhibitory signals to suppress the immune response. Alternative splicing results in multiple transcript variants. Polymorphisms in this gene have been associated with an increased risk of rheumatoid arthritis. [provided by RefSeq, Aug 2011]

Canonical amino-acid sequenceUniProt

289 residues, UniProt reviewed canonical sequence.

>Q7Z6A9|BTLA
     1  MKTLPAMLGT GKLFWVFFLI PYLDIWNIHG KESCDVQLYI KRQSEHSILA GDPFELECPV
    61  KYCANRPHVT WCKLNGTTCV KLEDRQTSWK EEKNISFFIL HFEPVLPNDN GSYRCSANFQ
   121  SNLIESHSTT LYVTDVKSAS ERPSKDEMAS RPWLLYRLLP LGGLPLLITT CFCLFCCLRR
   181  HQGKQNELSD TAGREINLVD AHLKSEQTEA STRQNSQVLL SETGIYDNDP DLCFRMQEGS
   241  EVYSNPCLEE NKPGIVYASL NHSVIGPNSR LARNVKEAPT EYASICVRS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against BTLA can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.54
Highest tissue expression: 27 nTPM

Expression across tissuesHPA

Tissue

tonsil: 27 nTPM
lymph node: 25 nTPM
appendix: 11 nTPM
spleen: 10 nTPM
thymus: 7.2 nTPM
small intestine: 3 nTPM

Single-cell type

b-cells: 121 nCPM
plasma cells: 33 nCPM
pdcs: 30 nCPM
cdc: 28 nCPM
t-cells: 16 nCPM
thymocytes: 10 nCPM

Immune cell

naive B-cell: 97 nTPM
memory B-cell: 65 nTPM
plasmacytoid DC: 25 nTPM
memory CD4 T-cell: 14 nTPM
naive CD4 T-cell: 13 nTPM
naive CD8 T-cell: 13 nTPM

Brain region

cerebral cortex: 1.2 nTPM
medulla oblongata: 0.5 nTPM
white matter: 0.5 nTPM
cerebellum: 0.4 nTPM
pons: 0.4 nTPM
basal ganglia: 0.3 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.79
gnomAD pLI: 0.02
gnomAD missense Z: 1.46
DepMap mean gene effect: 0.07
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

signaling receptor activity

Cellular components

plasma membrane

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads BTLA as an antibody target. Whether an autoantibody or antibody against BTLA could matter depends on whether native BTLA is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

BTLA is annotated at the cell surface, where native BTLA is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label BTLA as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...